Valuation: Orexo AB

Market Cap 541M 56.09M 49.01M 45.23M 41.69M 78.58M 5.4B 80.32M 213M 2.65B 211M 206M 9.11B P/E 2026 *
-1.48x
P/E 2027 * -2.13x
Enterprise Value 436M 45.19M 39.49M 36.44M 33.59M 63.31M 4.35B 64.72M 171M 2.13B 170M 166M 7.34B EV / Sales 2026 *
22.9x
EV / Sales 2027 * 14.5x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day-14.00%
1 week-33.28%
Current month-35.50%
1 month-26.29%
3 months-26.29%
6 months-50.14%
Current year-48.57%
1 week 14.88
Extreme 14.88
24.6
1 month 14.88
Extreme 14.88
25.45
Current year 14.88
Extreme 14.88
36
1 year 14.88
Extreme 14.88
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap.
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/3/25 Buy 1 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-14.00%-33.28%-17.13%-6.41% 56.09M
-0.10%+3.21%+59.45%+20.34% 315B
-1.20%-2.43%+23.24%-8.31% 67.81B
+0.35%+2.11%+37.84%+86.59% 9.23B
+0.34%+0.51%+5.21%-0.69% 8.56B
+1.53%-3.64%-22.91%+5.31% 4.18B
-11.03%-12.07%-8.02%+14.00% 3.59B
+1.87%+3.36%-46.36%+28.62% 3.55B
-0.35%-0.87%+48.55%+60.56% 2.79B
-7.41%-2.37%+3.91%-23.64% 2.09B
Average -3.00%-4.87%+8.38%+17.64% 41.68B
Weighted average by Cap. -0.36%+1.01%+49.30%+16.62%

Financials

2026 *2027 *
Net sales 19M 1.97M 1.72M 1.59M 1.47M 2.76M 190M 2.82M 7.47M 92.97M 7.4M 7.24M 320M 27.5M 2.85M 2.49M 2.3M 2.12M 4M 275M 4.09M 10.82M 135M 10.71M 10.48M 463M
Net income -375M -38.91M -34M -31.37M -28.92M -54.51M -3.75B -55.72M -147M -1.83B -146M -143M -6.32B -270M -28.06M -24.53M -22.63M -20.86M -39.32M -2.7B -40.19M -106M -1.32B -105M -103M -4.56B
Net Debt -105M -10.89M -9.52M -8.78M -8.1M -15.26M -1.05B -15.6M -41.3M -514M -40.91M -40.01M -1.77B -143M -14.84M -12.97M -11.96M -11.03M -20.79M -1.43B -21.25M -56.25M -700M -55.72M -54.49M -2.41B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
65
Date Price Change Volume
26-07-17 SEK 15.48 -14.00% 222,093
26-07-16 SEK 18.00 -16.28% 178,150
26-07-15 SEK 21.50 -4.23% 23,701
26-07-14 SEK 22.45 -3.44% 18,347
26-07-13 SEK 23.25 +0.22% 2,400
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise